Acrivon Therapeutics (ACRV)

• Market cap: $68.5M
• 1 day: -1.84%
• 5 days: -12.09%
• 1 month: -11.6%
• 3 months: 4.58%
• 6 months: -33.88%
• Year to date: -34.96%
• 1 year: 45.45%
• 5 years: -90.38%
• 10 years: -90.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Employees: 76